Clinical trials: Healthy Volunteers.
Rheumatoid Arthritis
Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are: 1.
- Trial name
- NCT06361199
- Testing
- Proximod
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Longevity Inc.
Volunteers
Voclosporin in Healthy Japanese Volunteers
The study is a single-centre, double-blind, placebo controlled, randomized, ascending multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic profiles of voclosporin.
- Trial name
- NCT02949999
- Testing
- Voclosporin
- Where
- Philippines
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aurinia Pharmaceuticals Inc.
Ocular Pain, Dry Eye
Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
The purpose of this study is to determine whether SYL1001 is safe for the prevention and treatment of ocular pain and dry eye syndrome.
- Trial name
- NCT01438281
- Testing
- SYL1001
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Infection, Human Immunodeficiency Virus
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
The purpose of the study is to determine the effect of multiple doses of BMS-955176 on the QT interval corrected with Fridericia's method (QTcF) in healthy subjects.
- Trial name
- NCT02576119
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
The purpose of this study is to assess the effect of multiple doses of ganaplacide and lumefantrine combination on the substrates of cytochrome P450 (CYP) 3A4 (midazolam), CYP2C8 (repaglinide), CYP2D6 (dextromethorphan), organic…
- Trial name
- NCT05236530
- Testing
- Midazolam, Repaglinide, Dextromethorphan
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices.
- Trial name
- NCT06003465
- Testing
- LY3437943, Test, Reference
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46
TA-46 single- and multiple-ascending dose study in healthy volunteers to investigate safety and PK. The protocol is conducted in four parts; Part A - Single Ascending doses of TA46 Part B - Multiple Ascending doses of TA-46 Part…
- Trial name
- NCT04410809
- Testing
- TA-46
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy
Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers
Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox®)
- Trial name
- NCT02273531
- Testing
- Asasantin ER, new formulation, Asasantin ER, present commercial formulation
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Device Study in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of two different devices that may be used to inject medication just under the skin. Participants will receive placebo; no active drug will be given.
- Trial name
- NCT04848402
- Testing
- On-Body Delivery System (OBDS)/Multiple Bolus Injector, Single Auto Injector
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Validation of the Stability of Diagnostic Biomarkers on Healthy Volunteers
Stability studies on the peripheral biomarkers (lncRNAs, sncRNAs, mRNAs, proteins, lipids/metabolites) measured by Firalis IVD test candidates and effect of gender, age, nutrition on their expression level
- Trial name
- NCT05160337
- Testing
- Biomarker based IVD tests
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Firalis SA
Healthy Participants, Chronic Spontaneous Urticaria
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
This is a Phase 1, randomized, double-blind, placebo-controlled, sequential, single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of intravenous (IV) infusions…
- Trial name
- NCT06072157
- Testing
- AK006-IV, AK006-SC
- Where
- 25 sites in United States, Canada
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Allakos Inc.
Healthy Volunteers
A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients
The purpose of this study is to determine the effect of food on the pharmacokinetics (how the drug concentrations change over time) of abiraterone acetate 1000 mg when administered as a single dose in healthy male volunteers.
- Trial name
- NCT01798628
- Testing
- Treatment A: abiraterone acetate, Treatment B: abiraterone acetate, Treatment C: abiraterone acetate
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cougar Biotechnology, Inc.
PHA1A
A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo
This study will evaluate the safety and tolerability of an intramuscular injection of SAB-176 intended for use as a pre/post prophylactic for influenza.
- Trial name
- SAB-176-103 (NCT06435936)
- Testing
- Single Ascending Dose of SAB-176
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
This study consists of two parts, ie, single dose part with young healthy subjects (Part 1) and single and multiple dose part with elderly healthy subjects (Part 2), to assess the safety, tolerability, pharmacokinetics and…
- Trial name
- NCT02005211
- Testing
- AZD3293
- Where
- Japan
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211
This study will examine the effect of an inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A4) and permeability glycoprotein 1 (P gp) (200 mg itraconazole) on the PK disposition of a 10 mg tablet of TD- 1211 administered orally to…
- Trial name
- NCT01568411
- Testing
- TD-1211, TD-1211+ itraconazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Glycyx Therapeutics
Healthy, Chronic Rhinosinusitis With Nasal Polyps
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with…
- Conditions
- Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
- Trial name
- NCT02743871
- Testing
- PF-06817024
- Where
- 20 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rare Diseases
A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.
This is a randomized, placebo controlled and double-blinded study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of a single dose (1 mg/kg) of emapalumab in adult healthy Japanese subjects.
- Trial name
- NCT04765553
- Testing
- NI-0501, Saline
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Swedish Orphan Biovitrum
Severe Hepatic Impairment
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
The primary objective of this study is to characterize the steady state plasma
- Trial name
- NCT03818672
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Healthy
Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg
The objective of this study was to investigate the bioequivalence of Oxybutynin Chloride Extended-Release Tablets, 15 mg (Mylan Pharmaceuticals Inc.) to Ditropan XL® Extended- Release Tablets, 15 mg (ALZA Corporation; Distributed…
- Trial name
- NCT00649272
- Testing
- Oxybutynin Chloride Extended-Release Tablets, 15 mg, Ditropan XL® Extended-release tablets, 15 mg
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.